Intravenous Solutions Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Intravenous Solutions Market Report is Segmented by Type (Total Parenteral Nutrition, Peripheral Parenteral Nutrition), Solution Composition (Saline, Carbohydrates, and More), Packaging Material (Glass Bottles, PVC Plastic Bags, and More), End User (Hospitals & Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Intravenous Solutions Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Intravenous Solutions Market with other markets in Healthcare Industry

Intravenous Solutions Market Analysis by Mordor Intelligence

The Intravenous Solutions Market size is estimated at USD 13.58 billion in 2025, and is expected to reach USD 17.66 billion by 2030, at a CAGR of 5.38% during the forecast period (2025-2030).

Growth stems from an accelerating shift toward precision-engineered formulations driven by artificial-intelligence dosing tools, rising surgical volumes, and a chronic-disease burden that intensifies demand for reliable parenteral therapies. Environmental legislation is hastening a transition away from PVC packaging, while government-backed onshoring initiatives seek to protect domestic supply after recent disaster-linked shortages. Leaders in the intravenous solutions market are therefore investing in vertically integrated manufacturing, AI-enabled nutritional platforms, and resilient logistics networks that can withstand climate and geopolitical shocks.

Key Report Takeaways

  • By type, total parenteral nutrition (TPN) led with 62.37% of intravenous solutions market share in 2024, yet peripheral parenteral nutrition (PPN) is expanding at an 8.42% CAGR to 2030.
  • By solution composition, saline solutions captured 53.14% of the intravenous solutions market in 2024, while lipid emulsions record the fastest 9.19% CAGR through 2030.
  • By packaging material, non-PVC polyolefin formats are advancing at a 9.58% CAGR, whereas PVC bags still held 47.36% share of the intravenous solutions market in 2024.
  • By end user, hospitals and clinics accounted for 69.24% revenue share in 2024; home-care settings show the highest 7.76% CAGR to 2030.
  • By geography, North America commanded 39.81% share in 2024, but Asia-Pacific is forecast to grow at 7.07% CAGR through 2030.

Segment Analysis

By Type: TPN Sustains Leadership While PPN Gains Momentum

Total parenteral nutrition generated the largest revenue, equal to 62.37% of intravenous solutions market share in 2024. AI-guided calculators now tailor amino-acid, lipid, and electrolyte loads to metabolic markers, transforming TPN into a precision tool rather than a static recipe. Demand remains entrenched in neonatal and oncologic wards where gut function is compromised. 

Peripheral Parenteral Nutrition, although accounting for a smaller base, is forecast to post the leading 8.42% CAGR. Home infusion programs favor PPN because peripheral lines avoid central-catheter infection risk and simplify nursing care. Multi-chamber PPN bags cut compounding errors, and stability-enhanced formulations extend hang times, supporting out-of-hospital uptake. The result is a steady re-balancing of volumes inside the intravenous solutions market as clinicians weigh risk, cost, and patient comfort.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Solution Composition: Lipid Emulsions Accelerate Beyond Saline Staples

Saline maintained a 53.14% revenue share in 2024, underscoring its ubiquity in resuscitation and dilution tasks. Nevertheless, omega-3 enriched lipid emulsions are advancing at 9.19% CAGR between 2025 and 2030. Composite products such as SMOFlipid curb hepatotoxicity and modulate inflammation, creating measurable survival benefits in ICU cohorts. 

Protein hydrolysates, carbohydrate blends, and trace-element cocktails enjoy niche growth as evidence supports tighter nutrient control during sepsis and trauma recovery. Research into heat-stable protein carriers that remain bioactive after pasteurization may soon eliminate cold-chain dependence, opening frontier markets and reinforcing geographical diversity of the intravenous solutions market.

By Packaging Material: Non-PVC Formats Push Sustainability Agenda

PVC bags still dominate on a unit basis with market share of 47.36% in 2024, but non-PVC polyolefin containers are recording the highest 9.58% CAGR. California’s phase-out deadlines have already diverted USD 1.2 billion of capital toward re-tooling, and European tenders increasingly demand DEHP-free products. 

Glass bottles and multilayer polypropylene vials cater to niche segments involving cytotoxics and biologics where material compatibility is paramount. Barrier-coated polyolefin films that slash water-vapor transmission extend shelf life for amino-acid solutions, adding resilience to the intravenous solutions market supply chain.

Intravenous Solutions Market: Market Share by Packaging Material
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Home Care Outpaces Institutional Settings

Hospitals and clinics secured 69.24% revenue share in 2024, reflecting entrenched inpatient protocols. Yet the home-care sub-segment is expanding 7.76% annually, powered by payer incentives and patient preference for familiar surroundings. Portable smart pumps transmit data to telehealth centers, allowing real-time dose adjustment. 

Ambulatory infusion suites occupy the middle ground by offering specialist staff without costly overnight stays. These hybrid models sustain broader access and propel the intravenous solutions market into community settings previously dominated by oral therapies.

Geography Analysis

North America retained the largest regional stake with 39.81% of 2024 revenue, backed by advanced hospital networks and early uptake of AI dosing software. Executive Order 14293 and parallel state incentives are now underwriting new sterile-fill facilities in the Midwest, dispersing risk away from hurricane-prone regions. High insurance penetration also supports premium pricing for innovative non-PVC bags, further boosting the region’s intravenous solutions market performance.

Asia-Pacific displays the strongest momentum with a forecast 7.07% CAGR through 2030. China’s provincial tenders favor local capacity additions, while India leverages low-cost fill-finish labor for export contracts. Japan channels R&D subsidies into emulsions enriched with long-chain fatty acids that meet stringent geriatrics guidelines. Rising prevalence of diabetes and obesity in Southeast Asia likewise elevates demand for electrolyte-controlled solutions, making the region a critical growth engine for the intravenous solutions market.

Europe shows steady expansion anchored in stringent quality rules that reward GMP compliance. Hospitals prioritize DEHP-free sourcing, accelerating non-PVC conversion and opening premium niches. Meanwhile, Eastern European contract manufacturers bid for supplemental production to backstop Western shortages. Collectively, these dynamics keep the intravenous solutions industry resilient despite environmental taxes and evolving pharmacopoeia standards.

Intravenous Solutions Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The three largest suppliers Baxter International, Fresenius Kabi, and B. Braun collectively command high share of global revenue, reflecting moderate concentration. Baxter couples IV fluids with infusion pumps to lock in system sales, while its 2024 rollout of 10 new injectables expanded hospital wallet share. Fresenius Kabi’s EUR 600 (USD 708.2) million biosimilar franchise lets it bundle biologics with supportive parenterals, differentiating its catalog. B. Braun’s USD 1.2 billion investment in non-DEHP production strengthens its appeal in sustainability-focused tenders.

Mid-tier players pursue partnerships to scale, exemplified by ICU Medical’s USD 200 million joint venture with Otsuka that yields 1.4 billion bags annually. Start-ups aim at AI-guided compounding services, seeking licensing deals with hospital pharmacies. Regulatory initiatives such as the FDA Advanced Manufacturing Technologies program further encourage continuous-manufacturing prototypes that promise shorter lead times and fewer sterility interventions. Competitive rivalry therefore hinges on capacity, compliance agility, and digital-health integration as firms contest share in the intravenous solutions market.

Intravenous Solutions Industry Leaders

  1. B. Braun SE

  2. ICU Medical Inc.

  3. Ajinomoto Co., Inc.

  4. Baxter International Inc.

  5. Grifols S.A.

  6. *Disclaimer: Major Players sorted in no particular order
Intravenous Solutions Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Mallinckrodt and Endo announced a merger to create a diversified pharmaceuticals leader with pro forma revenue of USD 3.6 billion and Adjusted EBITDA of USD 1.2 billion, integrating their sterile injectables and generics businesses to enhance manufacturing infrastructure and generate substantial operating synergies.
  • February 2025: Baxter International completed the sale of its Kidney Care business as part of strategic transformation, enabling focus on core IV solutions and infusion therapy segments while anticipating operational sales growth of 4-5% annually post-sale.
  • October 2024: B. Braun Medical announced the plan to ramp up production of intravenous (IV) saline fluids by 20% at its plants in Irvine, California, and Daytona Beach, Florida.
  • July 2024: Amneal Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for a new formulation of potassium phosphates in 0.9% sodium chloride injection, available in ready-to-use intravenous (IV) bags. This sterile presentation streamlines the administration process by minimizing the compounding steps typically clinicians require.

Table of Contents for Intravenous Solutions Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Adoption of AI-Enabled, Personalized Parenteral Nutrition Protocols
    • 4.2.2 Steady Rise in Chronic Disease Prevalence
    • 4.2.3 Rapid Growth of Home-Based and Ambulatory Care Models
    • 4.2.4 Ageing Global Population Coupled with Increased Surgical Intervention Volumes
    • 4.2.5 Emergence of Stability-Optimized Large-Volume Parenterals
    • 4.2.6 Government-Backed Onshoring Initiatives
  • 4.3 Market Restraints
    • 4.3.1 High Compliance Burden Associated With GMP
    • 4.3.2 Ongoing Supply Chain Constraints
    • 4.3.3 Environmental Scrutiny of Single-Use IV Plastics
    • 4.3.4 Clinical Shift Toward Subcutaneous and Enteral Administration Routes
  • 4.4 Porter’s Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitutes
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Type
    • 5.1.1 Total Parenteral Nutrition (TPN)
    • 5.1.2 Peripheral Parenteral Nutrition (PPN)
  • 5.2 By Solution Composition
    • 5.2.1 Saline
    • 5.2.2 Carbohydrates
    • 5.2.3 Amino-acid & Protein Hydrolysates
    • 5.2.4 Lipid Emulsions
    • 5.2.5 Electrolytes, Vitamins & Trace Elements
  • 5.3 By Packaging Material
    • 5.3.1 Glass Bottles
    • 5.3.2 PVC Plastic Bags
    • 5.3.3 Non-PVC/Polyolefin Bags
  • 5.4 By End User
    • 5.4.1 Hospitals & Clinics
    • 5.4.2 Ambulatory Surgery & Infusion Centres
    • 5.4.3 Home-Care Settings
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Baxter International Inc.
    • 6.3.2 B. Braun SE
    • 6.3.3 Fresenius Kabi AG
    • 6.3.4 Grifols S.A.
    • 6.3.5 ICU Medical Inc.
    • 6.3.6 Ajinomoto Co., Inc.
    • 6.3.7 Otsuka Pharmaceutical Co., Ltd.
    • 6.3.8 PHARMASYNTEZ JSC
    • 6.3.9 SGD Pharma
    • 6.3.10 Vifor Pharma Ltd.
    • 6.3.11 Hospira Inc. (Pfizer)
    • 6.3.12 JW Life Science Co., Ltd.
    • 6.3.13 Sichuan Kelun Pharmaceutical Co., Ltd.
    • 6.3.14 Terumo Corporation
    • 6.3.15 Aculife Healthcare Pvt. Ltd.
    • 6.3.16 SSY Group Limited
    • 6.3.17 Nipro Corporation
    • 6.3.18 Axa Parenterals Ltd.
    • 6.3.19 JMS Co., Ltd.
    • 6.3.20 Qilu Pharmaceutical Co., Ltd.

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Intravenous Solutions Market Report Scope

As per the report's scope, intravenous solutions are chemically prepared fluids administered in the body through venous circulation to maintain or replace the level of lost body fluid. The intravenous solutions market is segmented by type, solution composition, end-user, and geography. The type segment is further bifurcated into total and peripheral parenteral solutions. The solution composition is further divided into saline, carbohydrates, vitamins and minerals, and other solution compositions. The end-user segment is further segmented into hospitals and clinics, ambulatory centers, and home care settings. The geography segment is divided into North America, Europe, Asia-Pacific, Middle East, and Africa. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments.

By Type Total Parenteral Nutrition (TPN)
Peripheral Parenteral Nutrition (PPN)
By Solution Composition Saline
Carbohydrates
Amino-acid & Protein Hydrolysates
Lipid Emulsions
Electrolytes, Vitamins & Trace Elements
By Packaging Material Glass Bottles
PVC Plastic Bags
Non-PVC/Polyolefin Bags
By End User Hospitals & Clinics
Ambulatory Surgery & Infusion Centres
Home-Care Settings
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Type
Total Parenteral Nutrition (TPN)
Peripheral Parenteral Nutrition (PPN)
By Solution Composition
Saline
Carbohydrates
Amino-acid & Protein Hydrolysates
Lipid Emulsions
Electrolytes, Vitamins & Trace Elements
By Packaging Material
Glass Bottles
PVC Plastic Bags
Non-PVC/Polyolefin Bags
By End User
Hospitals & Clinics
Ambulatory Surgery & Infusion Centres
Home-Care Settings
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the intravenous solutions market?

The market stands at USD 13.58 billion in 2025 and is set to reach USD 17.66 billion by 2030.

Which product type dominates the intravenous solutions market?

Total Parenteral Nutrition leads with 62.37% market share, although Peripheral Parenteral Nutrition is growing faster at 8.42% CAGR.

Why are non-PVC containers gaining traction?

Environmental regulations such as California’s Toxic-Free Medical Devices Act are phasing out DEHP-containing PVC, driving 9.58% CAGR growth for polyolefin bags.

How is artificial intelligence influencing IV-solution demand?

AI platforms like Stanford’s TPN2.0 standardize individualized dosing, cutting error rates and boosting hospital efficiency, thereby increasing demand for customizable formulations.

Which region is expected to show the fastest growth?

Asia-Pacific is forecast to expand at 7.07% CAGR through 2030, propelled by healthcare infrastructure upgrades and a rising chronic-disease burden.

Page last updated on: July 1, 2025

Intravenous Solutions Market Report Snapshots